Absci Corporation

NasdaqGS ABSI

Absci Corporation Price to Earnings Ratio (P/E) on February 06, 2025: -5.55

Absci Corporation Price to Earnings Ratio (P/E) is -5.55 on February 06, 2025, a -40.73% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Absci Corporation 52-week high Price to Earnings Ratio (P/E) is -2.69 on June 20, 2024, which is 51.59% above the current Price to Earnings Ratio (P/E).
Absci Corporation 52-week low Price to Earnings Ratio (P/E) is -6.06 on April 09, 2024, which is -9.26% below the current Price to Earnings Ratio (P/E).
Absci Corporation average Price to Earnings Ratio (P/E) for the last 52 weeks is -4.36.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGS: ABSI

Absci Corporation

CEO	Mr. Sean McClain
IPO Date	July 22, 2021
Location	United States
Headquarters	18105 SE Mill Plain Boulevard
Employees	155
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies Fintech

Description

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Key trends

Past 5 years